Context Announces Presentation of New Preclinical Data on Apristor in Combination with a Cdk4/6 Inhibitor at San Antonio Breast Cancer Symposium

Apristor Shows Synergistic Activity in Combination with a SERD or Cdk4/6 Inhibitor in Preclinical Models of Breast Cancer

Highlights Company’s Leadership in Selective Progesterone Receptor Antagonism

Philadelphia, PA, November 14, 2018 – Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on Apristor®, its first-in-class full progesterone receptor antagonist, will be featured at the San Antonio Breast Cancer Symposium® taking place on December 4-8, 2018 in San Antonio, TX.

At the conference, Dr. Deepak Lala, Ph.D., Chief Technology Officer of Context Therapeutics will present preclinical data highlighting Apristor in inhibiting breast cancer cell proliferation alone or when combined with Palbociclib, a CDK4/6 inhibitor or FASLODEX® (Fulvestrant), an estrogen receptor antagonist. The study was conducted in collaboration with Dr. Carol Lange, Ph.D., Tickle Family Chair of Breast Cancer Research at the University of Minnesota, 

 

The poster details are as follows:

Poster Title: The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors in preclinical in-vitro breast cancer models

Poster: #926 (P6-20-13)

Session Date: Saturday, 12/8/2018

Session Time: 7:30 AM - 9:00 AM CT

Location: Henry B Gonzalez Convention Center/ Poster Hall 1

For more information on SABCS 2018, please visit https://www.sabcs.org

About Apristor

Apristor® (onapristone extended release) is Context’s wholly owned, first-in-class, orally active extended release formulation of onapristone, a full progesterone receptor antagonist.  Progesterone receptor [PR] plays a critical role in driving breast cancer disease progression as well as therapeutic resistance to first line antiestrogen or Cdk4/6 inhibitor therapy. Apristor is the only full PR antagonist that is being developed to target breast cancer. Apristor has the potential to transform the treatment of breast cancer, through the potent inhibition of PR signaling thereby blocking breast cancer cell proliferation and overcoming resistance to first line antiestrogen and Cdk4/6 inhibitor therapy.

About Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor® (onapristone extended release), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) cancers. In addition, Context is advancing CTX-30916, a preclinical progesterone receptor antagonist, and a discovery-stage program targeting Sigma1. For more information on Context, visit www.contexttherapeutics.com.

 

Context Contact

Context Therapeutics
Deepak Lala, PhD
Chief Technology Officer
dlala@contexttherapeutics.com

or

Investor Contact

Solebury Trout
Michael Levitan
MLevitan@troutgroup.com

 

1. Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, et al. (2018) Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS ONE 13(10): e0204973. https://doi.org/10.1371/journal.pone.0204973

News ReleasesMartin Lehr